retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism (LY3437943): of Action and Research Overview Eat Less & Burn More
Description
Preclinical studies have clearly demonstrated that GLP-1RAs effectively reduce hepatic macrophage infiltration and suppress expression of TNF- , IL-6, and other pro-inflammatory mediators in animal models of MASLD (21, 22)
These drugs are available as a daily or weekly injection or a daily pill
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
ADA guidance also notes benefits of GLP-1 RAs in diabetes patients who also have cardiovascular disease, chronic kidney disease, or obesity-linked complications
Perrotta, C., Cattaneo, M
